The development of biosimilars has been a strategy to reduce the rising cost of healthcare, particularly in the area of oncology. This course provides critical information on the approval of biosimilars, the clinical aspects of interchangeability, and the development of a collaborative process for quality care.
Upon successful completion of this application-based CPE course, pharmacists should be able to:
1. Define key terminology related to biosimilar products.
2. Explain the FDA’s process for developing, reviewing, and approving biosimilars.
3. Assess the impact of biosimilars on patients, payers, providers, and pharmacies in hematology/oncology practice.
4. Discuss the potential effects of an interchangeability designation for a biosimilar.
5. Develop a collaborative process for pharmacy team members to be more involved in substituting biosimilars.
Kelly Brunk, PharmD, BCOP
Clinical Oncology Pharmacist
The University of Kansas Health System
Dr. Brunk has no relevant financial relationships with ineligible companies to disclose.
Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Initial Release Date: October 4, 2022
Planned Expiration Date: October 4, 2025
Copyright 2022, CEimpact. All Rights Reserved. Any reproduction of this course without express permission is strictly forbidden.
CEImpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Obtain CPE credit by completing the course, followed by the exam and evaluation (if applicable). Once successfully completed, your course will appear in your Completed Courses tab. Access your CPE statement of credit at www.MyCPEMonitor.net.
¹CEImpact provides you with two (2) opportunities to complete the exam. The learner will not receive CPE credit after two failed attempts.
Disease State/Drug Therapy
01 Drug Therapy